The National Cancer Institute is soliciting proposals from small business concerns to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative technologies in the following areas:
- Development of therapeutic technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers.
- Development of devices or diagnostic technologies for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers.
For this solicitation rare cancers with a 5-year survival rate of less than 50 % are encouraged and rare cancers would be defined as including all the cancers listed by the NIH Genetics and Rare Diseases Information Center. The list can be found here: https://rarediseases.info.nih.gov/diseases/diseases-by-category/1/rare-cancers. Access the NCI Surveillance, Epidemiology, and End Results Program (SEER) database (https://seer.cancer.gov/) for more information regarding 5-year cancer survival rates.
Deadline: Aug. 22, 2023
To receive SBIR funds, each awardee must qualify as a small business concern (SBC) at the time of award and at any other time set forth in SBA's regulations at 13 CFR 121.701-121.705. Each applicant must qualify as a small business for research or research and development purposes and certify to this on the Cover Sheet of the proposal. Additionally, each awardee must submit a certification stating that it meets the size, ownership and other requirements of the SBIR Program at the time of award, and at any other time set forth in SBA's regulations at 13 CFR 121.701-705.